Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response
Frontiers in Bioscience-Landmark · 2025
DOI: 10.31083/fbl41531 ↗At a glance
Übersichtsarbeit in Frontiers in Bioscience-Landmark, 2025. Written by Yuanyuan Xu and 5 co-authors. Institution: Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030 Shanghai, China. Major MEDLINE topics: Gastrointestinal Microbiome, Lung Neoplasms, Immunotherapy, B7-H1 Antigen. Cited 6 times so far (Crossref); 119 references. The full text is freely available (open access, CC BY 4.0). Funded by: Shanghai Municipal Natural Science Foundation.
Abstract (original language)
Lung cancer, the leading cause of cancer-related mortality worldwide, poses considerable therapeutic challenges due to the varied responses to programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors. Emerging highlight the pivotal role of host-microbiome interactions in modulating antitumor immunity and influencing clinical outcomes. This review examines how the respiratory and gut microbiota contribute to the immunosuppressive tumor microenvironment through dysbiosis-induced T-cell exhaustion and regulatory cell activation, while certain commensals facilitate dendritic cell-mediated recruitment of cytotoxic T lymphocytes. Additionally, this review explores the molecular mechanisms by which microbial metabolites, such as short-chain fatty acids, influence myeloid-derived suppressor cells. Therapeutically, microbiota-modulation strategies—such as tailored probiotic formulations and precision fecal microbiota transplantation—offer potential to enhance immunotherapy efficacy. This review provides a foundation for microbiome-guided immunotherapy, advocating for biomarker-driven patient stratification and the use of engineered microbial consortia to counteract therapeutic resistance. These findings pave the way for the integration of microbiome science into next-generation precision oncology.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, 200030 Shanghai, China.
- Department of Thoracic Surgery, Fujian Medical University Union Hospital, 350000 Fuzhou, Fujian, China.
Funding
- Shanghai Municipal Natural Science Foundation
Cite
APA
Xu, Y., Tao, Y., Pan, H., Wang, Z., Wang, H., & Luo, Q. (2025). Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl41531
Vancouver
Xu Y, Tao Y, Pan H, Wang Z, Wang H, Luo Q. Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response. Frontiers in Bioscience-Landmark. 2025. doi:10.31083/fbl41531
BibTeX
@article{Xu2025,
author = {Xu, Yuanyuan and Tao, Yixing and Pan, Hanbo and Wang, Zhongjie and Wang, Hui and Luo, Qingquan},
title = {Microbiome Modulation in Lung Cancer Immunotherapy: Unveiling the Role of Respiratory and Gut Microbiota in the PD-1/PD-L1 Response},
journal = {Frontiers in Bioscience-Landmark},
year = {2025},
doi = {10.31083/fbl41531}
}
EUVIMED